Treatment for HIV-Infected Patients to Induce Long-Term Non-Progressor with Constant Drug Dosage |
Kim Jinyoung
(한양대 공대 전자전기컴퓨터공학부)
Kim Won Hee ((주)삼성전자 TN총괄) Ko Ji Hyun (McGill University 의대 신경과학부) Chung Han Byul (한양대 공대 전기공학과) Chung Chung Choo (한양대 공대 전자전기컴퓨터공학부) |
1 | M. Clerici, E. Seminari, F. Suter, et al, 'Different immunologic profiles characterize HIV infection in highly active antiretroviral therapy treated and antiretroviral-napatient with undetectable viraemia,' AIDS, vol. 14, pp. 109-116, 2000 DOI |
2 | J. Gerstoft, O. Kirk, N. Obel, C. Pedersen, L. Mathiesen, H. Nielsen, TL. Katzenstein, JD. Lundgren, 'Low efficacy and high frequency of adverse events in a randomized trial of the triple nucleoside regimen abacavir,' AIDS, vol. 17, pp. 2045-2052, 2003 DOI |
3 | M. A. Nowak and R. M. May,'Virus Dynamics: Mathematical principles of immunology and virology,' Oxford University Press, 2000 |
4 | R. A. Arnaout, M. A. Martin, and D. Wodarz, 'HIV-1 dynamics revisited: biphasic decay by cytotoxic T lymphocyte killing?,' In Proceedings of the Royal Society of London. series Biological sciences, vol. 267, pp. 1347-1354, 2000 |
5 | H. Shim, H. Chang, and J. Seo, 'Non-vanishing basin of attraction with respect to a parametric variation and center manifold,' In proceedings of IEEE Conference on Decision and Control, pp. 2984-2989, 2004 |
6 | A. M. Jeffrey, X. Xia, and I. K. Craig, 'When to inititate HIV therapy: a control theoretic approach,' IEEE Trans. On Biomedical Engineering, vol. 50, no 11, pp. 1213-1220, Nov. 2003 DOI ScienceOn |
7 | S. Kubiak, H. Lehr, R. Levy, T. Moeller, A. Parker and E. Swim, 'Control of HIV infection through structured treatment interruptions with recommendations for experimental protocol,' CRSC Technical Report (CRSC-TR01-27) pp. 1-20, 2001. (Also at http://www.math.montana.edu/-parker.) |
8 | 'Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents,' aidsinfo. nih.gov, March 23, 2004. [Online] Available: http://www.aidsinfo.nih.gov/guidlines/adult/AA_032304.html |
9 | H. Chang, H. Shim, and J. Seo, 'Control of immune response of HIV infection model by gradual reduction of drug dose,' In Proc. of Conference on Decision and Control, pp. 1048-1054, 2004 |
10 | J. H. Ko, W. H. Kim, and C. C. Chung, 'Optimized structured treatment interruption for HIV therapy and its performance analysis on controllability,' In Proc. of IEEE Conference on Decision and Control, pp. 1055-1060, 2004 |
11 | R. Zurakowski and A. R. Teel, 'Enhancing immune response to HIV infection using MPC-based treatment scheduling,' In proceedings of American Control Conference, pp. 1182-1187, 2003 DOI |
12 | 허영희, 고지현, 김진영, 정정주, 남상원, 심형보, 'HIV 동역학과 최적 제어를 이용한 약물 치료에 관한 고찰,' Journal of Control, Automation and Systems Engineering, vol. 10, No.6, pp. 475-486, June 2004 과학기술학회마을 DOI |
13 | 'Treatment interruptions,' factsheets, AIDS.org, April, 2003. [Online] Available: http://www.aids.org/factSheets/406-Treatment- Interruptions.html |
14 | 'What is AIDS,' factsheets, AIDS.org, November 22, 2003. [Online] Available: http://www.aids.org/factSheets/101-What-is-AIDS.html |
15 | D. Wodarz, 'Helper-dependent vs. helper -independent CTL responses in HIV infection: implications for drug therapy and resistance,' J. Theor. Biol., vol. 213, pp. 447-459, August 2001 DOI ScienceOn |
16 | H. Shim, S. J. Han, C. C. Chung, S. W. Nam and J. H. Seo, 'Optimal scheduling of drug treatment for HIV infection: continuous dose control and receding horizon control,' International Journal of Control, Automation, and Systems, vol. 1. no. 3, pp. 282-288, 2003 |
17 | D. Wodarz and M. A. Nowak, 'Specific therapy regimes could lead to long-term immunological control of HIV,' PNAS, vol. 96, pp. 14464-14469, December 1999 DOI |
18 | D. Douek, J. Brenchley, M. Betts, D. Ambrozak, B. Hill, Y. Okamoto, J. Casazza, J. Kuruppu, K. Kunstman, S. Wollnsky, Z. Grossman, M. Dybul, A. Oxenlus, D. Price, M. Conners, and R. Koup, 'HIV preferentially infects HIV-specific CD4+ T cells,' Nature, vol. 417, pp. 95-98, 2002 DOI ScienceOn |
19 | C. A. Janeway, P. Travers, M. Walport, and M. Shlomchik, 'Immunobiology,' Garland Churchill Livingstone, 2001 |
20 | S. Bonhoeffer, M. Rembiszewski, G. M. Ortiz, D. F. Nixon, 'Risks and benefits of structured antiretroviral drug therapy interruptions in HIV-1 infection,' AIDS, vol. 14, pp. 2313-2322, 2000 DOI ScienceOn |